Deloitte Legal assists with the sale of Syndesi Therapeutics SA to AbbVie Central Finance B.V. 

Deloitte Legal is proud to have assisted the syndicate of new Series B investors, consisting of INKEF Capital, Jeito Capital and Forbion, in respect of the EUR 80 million Series B financing round in Precirix NV.

Precirix NV is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labelled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage.

The proceeds of this financing round will fund the development and expansion of Precirix’s pipeline and, more specifically, will advance the product candidate through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the clinic. Precirix NV will also focus on further strengthening the platform, using its potential to generate new product candidates, linkers and CMC processes.

The Deloitte Legal Corporate and M&A team was led by Christoph Michiels and comprised team members Henri-Simon Vande Vyver and Elena Vromans.

Read the full press release here.